Managers
Essling Capital continues its unlisted co-investment programme with the launch of its third vintage fund, Essling Co-Invest 3 (ECI 3).
The launch of ECI 3 is taking place after completion under the previous fund, launched in 2018 for a total raised of EUR116 million, of an eighth and final investment in July – the acquisition of a minority stake in Funecap, the second largest company in the funeral services market in France, alongside management and Charterhouse.
Investors in the first fund have already been repaid nearly 80% of the invested amounts in three years, thanks to, among other things,
Henkel is to acquire Deva Parent Holdings from a fund managed by the Private Equity Group of Ares Management Corporation. Deva Parent Holdings owns DevaCurl, a high-growth professional hair care business.
Founded in 1994, the company offers hair care and styling products for all types of curly and wavy hair with a comprehensive portfolio of vegan and “free from” formulas. The product range includes cleansers, conditioners, styling products, styling accessories, and treatments. The portfolio of DevaCurl is highly complementary to the existing portfolio of Henkel Beauty Care. The ‘Premium Professional’ products of DevaCurl are distributed in the US in leading
Off the back of a hugely successful 2019, Le Col, the British brand renowned for delivering premium performance cycling apparel, has raised an additional GBP2.5 million from Puma Private Equity to further accelerate its growth plans in 2020.
Founded by ex-professional cyclist Yanto Barker in 2011, Le Col has its DNA in the pro peloton and has been kit partners to two men’s and two women’s professional cycling teams in the 2019 cycling season. The British company is based in London but manufactures its kit in its own factory in Treviso, Italy – an area renowned for expertise in high-performance
Providence Strategic Growth (PSG), the growth equity affiliate of Providence Equity Partners (Providence), has made a EUR32 million growth investment in Net Reviews, a developer of software as a service (SaaS) solutions providing customer review management for retailers.
The founding management team – led by Olivier Mouillet, Laurent Abisset and Tom Brami – will continue overseeing the company’s day-to-day operations.
Olivier Mouillet, Founder and CEO of Net Reviews, says: “In just a few years, Net Reviews has grown into a market-leading developer of software that provides a trustworthy and independent web solution, as well as critical data to retailers looking
CapitalRise, a property investment platform, has secured GBP1 million in backing from Revolt Ventures, the venture capital arm of real estate investment manager, Meyer Bergman.
This follows CapitalRise’s successful Seedrs crowdfunding raise earlier this year and brings the total funds raised to GBP3.3 million.
CapitalRise’s CEO and Co-Founder, Uma Rajah, says: “To receive backing from such eminent investors reflects sustained confidence in our proposition. Our track record delivering strong returns at an average 10 per cent per annum with zero losses and defaults since inception reflects our vigilance and strict due diligence when it comes to choosing investment opportunities.
The Riverside Company (Riverside), a global private equity firm focused on the smaller end of the middle market, has sold surgical device tracking and workflow software provider, Censis Technologies (Censis).
Headquartered in Franklin, Tennessee, Censis provides SaaS-based surgical instrument tracking and workflow solutions for sterile processing departments (SPDs) of hospitals and ambulatory surgical centres.
Censis helps ensure the accuracy and procedural compliance of SPDs, including the critical responsibility of assembling instrument trays for surgical procedures, sterilising instruments and managing and maintaining inventory from purchase to retirement.
Riverside Managing Partner, Loren Schlachet, says: “Our team had a clear value
Clients of Connection Capital, a specialist private client investment business, have invested in the final close of a North America and Europe-focused lower mid-market private equity fund, run by the highly experienced global team at TriSpan, the New York and London-based private equity manager.
As per Connection Capital’s investment model, its high net worth (HNW) private investor and family office clients were able to participate in the TriSpan Opportunities Fund in units of just GBP25,000 (the usual minimum investment in USD1 million) via a Connection Capital investment vehicle that, in total, substantially exceeded the minimum investment threshold of the TriSpan
Moody’s Analytics Knowledge Services has rebranded as Acuity Knowledge Partners (Acuity) following the completion of its management buyout from Moody’s Corporation, supported by the European mid-market private equity investor Equistone Partners Europe (Equistone).
Acuity, a leading provider of bespoke research, analytics and automation technology to the financial services sector, has also appointed Philip Gore-Randall as Non-Executive Chairman.
Under its new brand identity and with Equistone’s backing, Acuity will continue to provide market-leading customised knowledge services to a growing, blue-chip client base of over 300 financial services firms globally, in domains such as investment banking, investment research, private equity &
A new survey of senior private equity professionals reveals that only 23 per cent describe the due diligence that private equity firms carry out on cyber security issues of target companies as ‘good’ or ‘excellent’.
The research, which was commissioned by Mactavish, the leading expert on commercial insurance placement and disputes, reveals that 30 per cent of the private equity professionals interviewed describe the industry’s work here as ‘average’, and 27 per cent them said it was ‘poor’ or ‘terrible.’
However, the findings suggest future potential improvements in this area, as 83 per cent of respondents expect private equity firms
Stone Capital and Biosyngen have partnered to establish a USD50 million biopharmaceutical investment Fund in Singapore for the Biosyngen biopharmaceutical technology transfer platform and to incubate companies.
Biosyngen has been an angel investment platform for biopharmaceutical projects, who has formed projects with selected early stage technologies after stringent screening process. This fund allows Biosyngen to take advantage of Singapore pool of talent, technology, regulations, government support and other industrial resources, in particular cell therapy technologies, Biosyngen provides high-efficient incubation support and clinical transformation of the projects. The Company is also taking advantage of the Chinese government’s policy support, environment and
Events
12 November, 2026 – 8:00 am
12 November, 2026 – 5:00 pm
